0 Datasets
0 Files
Get instant academic access to this publication’s datasets.
Yes. After verification, you can browse and download datasets at no cost. Some premium assets may require author approval.
Files are stored on encrypted storage. Access is restricted to verified users and all downloads are logged.
Yes, message the author after sign-up to request supplementary files or replication code.
Join 50,000+ researchers worldwide. Get instant access to peer-reviewed datasets, advanced analytics, and global collaboration tools.
✓ Immediate verification • ✓ Free institutional access • ✓ Global collaborationJoin our academic network to download verified datasets and collaborate with researchers worldwide.
Get Free AccessWe performed a systematic review to assess the available evidence of FDG-PET utility in the diagnosis of Amyotrophic Lateral Sclerosis (ALS) with and without cognitive impairment. The search was performed on Medline, Embase and Cochrane on November 20, 2015. Critical outcomes for this PICO are sensitivity, specificity and accuracy of FDG-PET in distinguishing patients with ALS from patients with other pathologies or healthy people, as assessed versus clinical diagnosis. Minimum sample size was set at 10 subjects with the target condition. Data were extracted and assessed as to publication bias, heterogeneity, imprecision, risk of bias, indirectness, and applicability. We provide assessment of the quality of evidence, of the target effect, and of strength of recommendation. Out of the 16 papers selected, 2 reported the outcomes of interest. These provided moderate quality of evidence (Table) that hypometabolic regions including the prefrontal cortex, thalamus, primary motor cortex, striatum and posterior cingulate can distinguish ALS patients from healthy controls with 94.8–95.4% sensitivity, 80.0–82.5% specificity and 91.8–93.2% accuracy (Laere et al., 2014; and Pagani et al., 2014). Concerns regarding the applicability of FDG-PET as assessed here are due to the use of semiquantitative methods of image analysis (increasingly but not yet routinely adopted in clinical context). The available data provide moderate quality of evidence for high diagnostic utility of FDG-PET in distinguishing ALS patients from healthy controls. However, all studies were performed considering baseline clinical diagnosis as the reference standard, raising doubt on either methodological validity or the actual clinical usefulness of FDG-PET in improving clinical diagnosis. We conclude for a doubtful recommendation for clinical use of FDG-PET in the diagnosis of ALS. Further research is warranted to provide proper assessment of the incremental value of FDG-PET on this issue.
Daniele Altomare, Stefania Orini, Federica Agosta, Elisabetta Sarasso, Cristina Festari, Massimo Filippi, Marina Boccardi (2017). [IC‐P‐067]: DIAGNOSTIC UTILITY OF FDG‐PET TO CONFIRM A CLINICAL SUSPICION OF AMYOTROPHIC LATERAL SCLEROSIS. , 13(7S_Part_1), DOI: https://doi.org/10.1016/j.jalz.2017.06.2340.
Datasets shared by verified academics with rich metadata and previews.
Authors choose access levels; downloads are logged for transparency.
Students and faculty get instant access after verification.
Type
Article
Year
2017
Authors
7
Datasets
0
Total Files
0
Language
en
DOI
https://doi.org/10.1016/j.jalz.2017.06.2340
Access datasets from 50,000+ researchers worldwide with institutional verification.
Get Free Access